{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:07Z","timestamp":1786980487863,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,6,7]],"date-time":"2015-06-07T00:00:00Z","timestamp":1433635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s10067-015-2988-9","type":"journal-article","created":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T01:01:06Z","timestamp":1433552466000},"page":"1059-1064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study"],"prefix":"10.1007","volume":"35","author":[{"given":"Arvind","family":"Chopra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chandrashekara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajgopalan","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Rajasekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarathchandra Mouli","family":"Veeravalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alakendu","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrugank","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotsna","family":"Oak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Londhey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,7]]},"reference":[{"key":"2988_CR1","unstructured":"WHO: Chronic diseases and health promotion: chronic rheumatic conditions. http:\/\/www.who.int\/chp\/topics\/rheumatic\/en\/ . Last accessed 04 Feb 2014"},{"issue":"2 suppl 1","key":"2988_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200422001-00002","volume":"22","author":"TK Kevin","year":"2004","unstructured":"Kevin TK (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(2 suppl 1):1\u201312","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"2988_CR3","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/rheumatology\/ket222","volume":"52","author":"A Chopra","year":"2013","unstructured":"Chopra A (2013) The COPCORD world of musculoskeletal pain and arthritis [editorial]. Rheumatology 52(11):1925\u20131928","journal-title":"Rheumatology"},{"issue":"6","key":"2988_CR4","first-page":"1037","volume":"72","author":"JA Rindfleisch","year":"2005","unstructured":"Rindfleisch JA, Muller D (2005) Diagnosis and management of rheumatoid arthritis. Am Fam Physician 72(6):1037\u20131047","journal-title":"Am Fam Physician"},{"key":"2988_CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1517\/13543780903418452","volume":"19","author":"PH Carter","year":"2010","unstructured":"Carter PH, Zhao Q (2010) Clinically validated approaches to the treatment of autoimmune diseases. Expert Opin Investig Drugs 19:195\u2013213","journal-title":"Expert Opin Investig Drugs"},{"key":"2988_CR6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.rinim.2012.11.001","volume":"2","author":"PC Rodriguez","year":"2012","unstructured":"Rodriguez PC, Torres-Moya R, Reyes G et al (2012) A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Res Immunol 2:204\u2013211","journal-title":"Res Immunol"},{"key":"2988_CR7","doi-asserted-by":"crossref","unstructured":"Alonso-Ramirez R, Loisel S, Buors C et al (2011) Rationale for targeting CD6 as a treatment for autoimmune diseases. Arthritis Published Online First: 10 February 2011. doi: 10.1155\/2010\/130646","DOI":"10.1155\/2010\/130646"},{"issue":"3","key":"2988_CR8","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jaad.2014.01.897","volume":"71","author":"DS Krupashankar","year":"2014","unstructured":"Krupashankar DS, Dogra S, Kura M et al (2014) Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol 71(3):484\u2013492","journal-title":"J Am Acad Dermatol"},{"key":"2988_CR9","doi-asserted-by":"crossref","unstructured":"Blumenauer BBTB, Judd M, Wells GA, et al (2002) Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev Issue 3. Art. No.: CD003785. doi: 10.1002\/14651858.CD003785","DOI":"10.1002\/14651858.CD003785"},{"issue":"8","key":"2988_CR10","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","volume":"67","author":"M Schiff","year":"2008","unstructured":"Schiff M, Keiserman M, Codding C et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67(8):1096\u20131103","journal-title":"Ann Rheum Dis"},{"key":"2988_CR11","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","volume":"46","author":"S Bombardieri","year":"2007","unstructured":"Bombardieri S, Ruiz AA, Fardellone P et al (2007) Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 46:1191\u20131199","journal-title":"Rheumatology (Oxford)"},{"key":"2988_CR12","doi-asserted-by":"crossref","unstructured":"Lethaby A, Lopez-Olivo MA, Maxwell L et al (2013) Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev Issue 5. Art. No.: CD004525. doi: 10.1002\/14651858.CD004525.pub2","DOI":"10.1002\/14651858.CD004525.pub2"},{"issue":"9","key":"2988_CR13","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54(9):2793\u20132806","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-2988-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-015-2988-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-2988-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T04:34:27Z","timestamp":1566794067000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-015-2988-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,7]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["2988"],"URL":"https:\/\/doi.org\/10.1007\/s10067-015-2988-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,7]]}}}